What is BG Medicine Inc?
, a diagnostics company, engages in the development and commercialization of novel cardiovascular diagnostic tests to address unmet medical needs in the United States, Europe, and internationally.
BGMD · Verdict
Moderate reward · elevated risk
BGMD's standout is balance sheet; volatility and profitability weigh on the picture.
Based on 63% data coverage
BGMD · Verdict
Top decile vs peers
Weak vs peers
-903% return on equity
Model-based scoring. For information only — not financial advice.
, a diagnostics company, engages in the development and commercialization of novel cardiovascular diagnostic tests to address unmet medical needs in the United States, Europe, and internationally. It offers BGM Galectin-3 test, a novel diagnostic test that measures galectin-3 in blood plasma or serum; and CardioSCORE test that is designed to identify cardiovascular events, such as heart attack and stroke. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.14K.
The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.